Contact Information: CONTACT: Alison Koski Text100 212-331-8436 AlisonK@text100.com Isa Loundon IntraLinks 212-342-7508 iloundon@intralinks.com
Intralinks Survey: Life Sciences Deal Activity Will Increase in 2010
More Than Half of Industry Executives Anticipate Multiple Deals Next Year
| Source: IntraLinks
NEW YORK, NY--(Marketwire - November 18, 2009) -
IntraLinks/BioNetwork West 2009 Facts:
-- IntraLinks®, the leading
provider of critical information exchange solutions, today announced the
results of a survey of key decision makers attending the BioNetwork West 2009
conference on their anticipated deal activity in 2010 and the ways they
expect to conduct them.
-- IntraLinks' Alison
Shurell, VP of Product Marketing, spoke on the conference's keynote
panel, "Adopting
Best Practices to Expedite Due Diligence," with Kevin Kuehm, VP Global
Transactions and BD&L for Bayer Healthcare, Anne
Dollard, Deputy General Counsel and Chief Patent Counsel for Takeda San Francisco and Jim
Hattersley, VP Business Development at Sun Pharmaceutical Industries.
-- For the past ten years, IntraLinks virtual datarooms have expedited the
due diligence activity of hundreds of licensing, financing and M&A deals
for pharmaceutical, biotech and medical devices companies. In addition to
supporting business development & licensing activity, IntraLinks also
allows sponsors and CROs to better manage, track and exchange regulatory
documents with investigators during clinical trials through IntraLinks'
secure, online platform.
Survey Facts:
-- Key survey findings:
- 92 percent of survey respondents indicated they expect to see some level
of deal activity in the next 12 months. Of that group, 57 percent of survey
respondents indicated they expect to do 1-4 deals.
- More than half of survey respondents indicated that 50-100 percent of
their deals are done using a virtual
dataroom (VDR).
- 96 percent of survey respondents indicated that some portion of their
deals include large, linked documents such as Investigational New Drug
Applications (INDs), Non-disclosure Agreements (NDAs), among others. Of
that group, 33 percent indicated that this is the case in the majority
(76-100 percent) of their deals.
-- Survey participants included top decision makers and executives from
major life sciences and pharmaceutical companies including: Bayer, Eli Lilly (LLY), GlaxoSmithKline (GSK), Madeira, Merck (MRK), New Link Genetics, Novartis (NVS), Proctor & Gamble (PG),
Sanofi-Aventis, Shire
Pharmaceuticals (SHPGY),
and Watson Pharma (WPI).
Supporting Quotes:
-- "The conference facilitated networking between members of the Life
Sciences community -- from biotechs to big pharma and everyone in between,"
said Alison Shurell,
VP of Product Marketing for IntraLinks. "The atmosphere was friendly --
people were there because they wanted to connect with others to discuss
promising compounds, technology and pipelines and explore possible
partnerships."
-- "The overall results of this survey reflect a trend we are seeing in the
Life Sciences industry of companies looking to move their critical
information to a secure online environment that is controlled and
compliant, like IntraLinks' solution," said Alison Shurell, VP of
Product Marketing for IntraLinks. "Physical due diligence is truly becoming
a thing of the past."
-- "Life sciences deals such as licensing deals include large, linked
documents; more than a third of survey respondents indicated this is true
for the majority (76-100 percent) of their deals," said Alison Shurell, VP of
Product Marketing for IntraLinks. "This affirms what we've been hearing
from clients, and underlines the need for a solution that can maintain the
integrity of the links in documents such as INDs, NDAs and other regulatory
documents when you move the process online. IntraLinks is the only solution
on the market with this capability, allowing potential partners to conduct
all of their due diligence activity in a secure, online environment."
Supporting Resources/Related Links:
-- Alison Shurell's Presentation via IntraLinks' Blog:
http://blog.intralinks.com/blog/2009/10/15/bionetwork-2009-keynote-panel-adopting-best-practices-expedite-due-diligence-process
-- BioNetwork West 2009 Presentations:
http://www.wbresearch.com/bionetworkwest/Presentations.aspx
-- Company Announcements:
- IntraLinks
Accelerates Drug Funding in the Pipeline for Fast Forward (August 27,
2009)
- IntraLinks
Announces Partnership with Adobe Systems Inc. to develop New Tool for Life
Sciences Data Capture and Submission-Based Business (November 4, 2009)
-- Company Demo: Life
Sciences
-- Whitepaper:
Clinical Document Exchange Portals: "Faster Study Start-up and Reduced
Costs Through the use of Clinical Document Exchange Portals"
About IntraLinks
IntraLinks provides on-demand solutions for businesses to securely
collaborate, communicate and exchange critical information inside and
outside the enterprise. For more than a decade, 750,000 professionals from
more than 90,000 organizations have relied on IntraLinks to accelerate
workflow, optimize business processes and realize new profit potential.
IntraLinks counts 800 of the Fortune 1000 as clients, including AstraZeneca
Pharmaceuticals LP, Bank of America, Deutsche Bank and the FDIC. For more
information, please visit www.intralinks.com, http://blog.intralinks.com/,
or http://twitter.com/intralinks.